PMID- 36137611
OWN - NLM
STAT- MEDLINE
DCOM- 20220926
LR  - 20221014
IS  - 1464-5157 (Electronic)
IS  - 0265-6736 (Linking)
VI  - 39
IP  - 1
DP  - 2022
TI  - Evaluating the long-term survival benefits of high intensity focused ultrasound 
      ablation for hepatocellular carcinoma with portal vein tumor thrombus: a single 
      center retrospective study.
PG  - 1245-1253
LID - 10.1080/02656736.2022.2122595 [doi]
AB  - AIMS: To evaluate the long-term survival benefits of high intensity focused 
      ultrasound (HIFU) ablation in patients with hepatocellular carcinoma (HCC) 
      combined with portal vein tumor thrombus (PVTT). METHODS: The data of patients 
      with HCC-PVTT treated with HIFU from January 2014 to December 2019 were 
      retrospectively analyzed. All patients received HIFU ablation for both PVTT and 
      liver tumor in one session. Perioperative adverse events (AEs) were recorded, and 
      follow-up was performed postoperatively. The Kaplan-Meier method was used for 
      survival analysis. RESULTS: Median follow-up was 13.75 +/- 1.31 months. A total of 
      144 patients (male/female: 122/22, age: 54.15 +/- 11.84 years old) were included in 
      the study. A total of 267 liver tumors (tumor number: 1.87 +/- 1.65, range 1-10) 
      were treated with HIFU. The mean +/- SD diameter of viable liver tumors was 
      100.98 +/- 61.65 mm. The reported postoperative AEs of HIFU were skin edema 
      (93.75%), local pain (69.44%) and fever (7.64%). There was no liver failure, 
      gastrointestinal bleeding or perioperative death. The median overall survival 
      (OS) time was 14 months, while the cumulative survival rates of 0.5, 1, 2 and 
      3 years were 79.0%, 58.6%, 33.3% and 5.9%, respectively. The median OS of PVTT 
      types I, II and III was 22, 13 and 14 months, respectively, and the difference 
      was not statistically significant (p > 0.05). CONCLUSION: HIFU is a minimally 
      invasive method for HCC-PVTT with fewer complications, which could prolong the 
      OS. Patients with PVTT type III could benefit more from HIFU, compared to types I 
      and II.
FAU - Chen, Xing
AU  - Chen X
AUID- ORCID: 0000-0002-8724-4950
AD  - State Key Laboratory of Ultrasound in Medicine and Engineering, College of 
      Biomedical Engineering, Chongqing Medical University, Chongqing, China.
AD  - Chongqing Key Laboratory of Biomedical Engineering, Chongqing Medical University, 
      Chongqing, China.
FAU - Ma, Yuhong
AU  - Ma Y
AUID- ORCID: 0000-0002-5345-5522
AD  - Clinical Center for Tumor Therapy, The Second Affiliated Hospital, Chongqing 
      Medical University, Chongqing, China.
FAU - Zhang, Jun
AU  - Zhang J
AUID- ORCID: 0000-0001-5659-1629
AD  - Clinical Center for Tumor Therapy, The Second Affiliated Hospital, Chongqing 
      Medical University, Chongqing, China.
FAU - Yang, Wei
AU  - Yang W
AUID- ORCID: 0000-0003-2798-0769
AD  - Clinical Center for Tumor Therapy, The Second Affiliated Hospital, Chongqing 
      Medical University, Chongqing, China.
FAU - Jin, Chengbing
AU  - Jin C
AUID- ORCID: 0000-0003-0039-8226
AD  - Clinical Center for Tumor Therapy, The Second Affiliated Hospital, Chongqing 
      Medical University, Chongqing, China.
FAU - Ran, Lifeng
AU  - Ran L
AUID- ORCID: 0000-0003-3721-7468
AD  - Clinical Center for Tumor Therapy, The Second Affiliated Hospital, Chongqing 
      Medical University, Chongqing, China.
FAU - Zhu, Hui
AU  - Zhu H
AUID- ORCID: 0000-0002-2001-6312
AD  - Clinical Center for Tumor Therapy, The Second Affiliated Hospital, Chongqing 
      Medical University, Chongqing, China.
FAU - Bai, Jin
AU  - Bai J
AUID- ORCID: 0000-0002-7959-5048
AD  - State Key Laboratory of Ultrasound in Medicine and Engineering, College of 
      Biomedical Engineering, Chongqing Medical University, Chongqing, China.
AD  - Chongqing Key Laboratory of Biomedical Engineering, Chongqing Medical University, 
      Chongqing, China.
FAU - Zhou, Kun
AU  - Zhou K
AUID- ORCID: 0000-0002-1599-8630
AD  - Clinical Center for Tumor Therapy, The Second Affiliated Hospital, Chongqing 
      Medical University, Chongqing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int J Hyperthermia
JT  - International journal of hyperthermia : the official journal of European Society 
      for Hyperthermic Oncology, North American Hyperthermia Group
JID - 8508395
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Carcinoma, Hepatocellular/complications/pathology/surgery
MH  - *Chemoembolization, Therapeutic/methods
MH  - Female
MH  - *High-Intensity Focused Ultrasound Ablation
MH  - Humans
MH  - *Liver Neoplasms/complications/pathology/surgery
MH  - Male
MH  - Middle Aged
MH  - Portal Vein/surgery
MH  - Retrospective Studies
MH  - *Thrombosis/complications/pathology/therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Hepatocellular carcinoma
OT  - high intensity focused ultrasound ablation
OT  - portal vein tumor thrombus
OT  - survival analysis
OT  - thermal ablation
EDAT- 2022/09/23 06:00
MHDA- 2022/09/28 06:00
CRDT- 2022/09/22 20:43
PHST- 2022/09/22 20:43 [entrez]
PHST- 2022/09/23 06:00 [pubmed]
PHST- 2022/09/28 06:00 [medline]
AID - 10.1080/02656736.2022.2122595 [doi]
PST - ppublish
SO  - Int J Hyperthermia. 2022;39(1):1245-1253. doi: 10.1080/02656736.2022.2122595.